查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球体外诊断市场评估：依产品类型、技术、环境、应用、最终用户、地区、机会、预测（2016-2030）
市场调查报告书
商品编码
1415580

全球体外诊断市场评估：依产品类型、技术、环境、应用、最终用户、地区、机会、预测（2016-2030）

Global In-vitro Diagnostics Market Assessment, By Product Type, By Techniques, By Settings, By Application, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 394 Pages | 商品交期: 3-5个工作天内

价格

全球体外诊断市场规模预计将从2022年的1,077.1亿美元增至2030年的1,655.5亿美元，2022-2030年预测期间复合年增长率为5.52%。

由于 IVD 设备的需求和采用不断增加，IVD 设备市场呈现显着成长。这种扩张得到了领先公司增加研发投资的进一步支持，以创新产品并开发 IVD 技术的新应用。据英国体外诊断协会称，这些测试对约 70% 的临床决策有显着影响。此外，诊断技术的进步保持了市场持续扩张的趋势。

世界各地癌症和遗传异常等慢性疾病的盛行率不断增加，增加了对体外诊断的需求。人们越来越意识到早期诊断可以挽救患者的生命，这推动了对体外诊断产品的需求。体外诊断在诊断疾病和预测未来发生的有效性正在进一步加速市场成长。

2023 年 1 月，QIAGEN 宣布推出适用于诊断实验室的 EZ2 Connect MDx。EZ2 Connect MDx 使实验室能够利用先进的自动化技术在 30 分钟内同时纯化 24 个样本中的 DNA 和 RNA。该设备带有 CE-IVD 合格标誌，在欧盟 (EU) 和其他国家/地区也有效。

膝骨关节炎盛行率高

包括遗传疾病、心血管疾病和神经系统疾病在内的各种疾病的盛行率不断上升，给医疗保健系统带来了巨大的负担。有效利用体外诊断（IVD）进行早期疾病检测使医生能够更有效地实施适当的治疗。例如，根据世界卫生组织2022年9月发布的情况说明书，非传染性疾病（NCD）导致的死亡人数为4,100万人，约占全球死亡总数的74%。

全球 IVD 市场可以透过提高患者和医生层面对早期诊断和 IVD 最佳使用的认识，有效解决日益增长的疾病负担。随着人口老化，人们更容易患高血压、糖尿病、心血管疾病、肝病和肾臟病等各种疾病，导致家庭医疗保健越来越多地采用体外诊断设备。

例如，联合国2023年1月报告称，2021年全球65岁及以上人口为7.61亿，预计2050年将增至16亿。80岁及以上的人口成长速度更快。

更多采用现场护理测试设备

随着疾病负担持续加重，医疗设备製造商正在努力开发利用先进技术的诊断设备。为此，医院和实验室越来越多地使用现场检测设备来寻找准确、即时的数据。即时护理 (PoC) 测试在患者附近进行，通常只需要少量血液样本，并提供快速测试结果以供立即临床决策。这项功能使医生能够快速做出治疗决定，而无需等待中心实验室的结果。

FUJIFILM Sonosite, Inc. 透露计划于 2023 年 1 月在印度推出 Sonosite PX 超音波系统。该新产品旨在改善临床医生的人体工学和效率并提高医疗绩效。

例如，2023年8月，Anbio Biotechnology进入即时检测市场，推出了一款基于LAMP诊断方法的手持式分析仪，用于快速即时检测。

增加资金和政府支持

在全球 IVD 市场中，政府机构、组织和机构正在透过宣传活动积极推广 IVD 的使用，这推动了市场的成长。世界卫生组织 (WHO) 推出了具有初级卫生保健基本体外诊断和临床实验室的卫生设施示范清单，强调了解决疾病负担和盛行率的重要性。这些类别进一步划分为涵盖一般体外诊断和特定疾病。

本报告研究和分析了全球体外诊断市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章执行摘要

第四章 2016-2030年全球体外诊断市场展望

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按产品类型
    • 用具
    • 试剂、耗材
    • 数据管理软件
  • 依方法
    • 免疫诊断
    • 临床化学
    • 分子诊断
    • 微生物学
    • 血液学
    • 凝血、止血
    • 尿液分析
    • 其他
  • 按环境
    • 实验室
    • 护理点
  • 按用途
    • 眼科
    • 感染
    • 糖尿病
    • 药物测试/基因组药理学
    • 自身免疫性疾病
    • 心脏病
    • 瘤
    • HIV爱滋病
    • 肾
    • 肠胃科
    • 其他
  • 按最终用户
    • 临床实验室
    • 医院
    • 即时检测中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市场占有率：依公司划分（2022 年）

第五章 全球体外诊断市场前景：依地区划分（2016-2030）

  • 北美
    • 市场规模及预测
    • 按产品类型
    • 依方法
    • 按环境
    • 按用途
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 意大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第六章 市场测绘（2022）

  • 按产品类型
  • 依方法
  • 按环境
  • 按用途
  • 按最终用户
  • 按地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第九章 监理架构与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/最新技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2022 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）

第11章案例研究

第十二章 主要公司展望

  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • BD (Becton, Dickinson, and Company)
  • Sysmex Corporation
  • Illumina, Inc.
  • Quidel Corp
  • BioMerieux SA
  • Charles River Laboratories
  • Bio-Rad Laboratories, Inc
  • DiaSorin S
  • Agilent Technologies, Inc
  • Qiagen
  • Seegene Inc

第十三章 战略建议

第十四章关于我们公司、免责声明

Product Code: MX10307

Global In-vitro diagnostics market is projected to witness a CAGR of 5.52% during the forecast period 2022-2030F, growing from USD 107.71 billion in 2022 to USD 165.55 billion in 2030. In-vitro diagnostics (IVD) refers to medical instruments designed to conduct diagnostic tests on biological samples like blood, urine, and tissues. These tests are crucial in identifying and tracking infectious diseases, autoimmune disorders, and various medical conditions. Additionally, they are utilized to assess adjustments in drug therapy at regular intervals.

The market for IVD devices is experiencing significant growth due to increasing demand for and adoption of these devices. This expansion is further propelled by key players' heightened investments in research and development, aiming to innovate products and explore new applications for IVD techniques. The British In-vitro Diagnostic Association says these tests significantly impact around 70% of clinical decisions. Furthermore, technological advances in diagnostics sustain a tendency for continual market expansion.

The rising prevalence of chronic diseases like cancer and genetic anomalies across the globe is raising the demand for more in-vitro diagnostics procedures. Growing awareness about early diagnosis can save significant prospective patients and is driving the call for in-vitro diagnostics products. The efficacy of in-vitro diagnostics in diagnosing and predicting the future occurrence of diseases is further propelling the market growth.

In January 2023, QIAGEN announced the launch of EZ2 Connect MDx for diagnostic laboratories. EZ2 Connect MDx can help labs purify DNA and RNA from 24 samples simultaneously within 30 minutes with a high degree of automation. The device has gained the EU's CE-IVD compliance marking valid in the European Union and in other countries as well.

High Prevalence of Knee-Associated Osteoarthritis

The increasing incidence of various diseases, including genetic, cardiovascular, and neurological conditions, substantially strains the healthcare system. The effective utilization of In Vitro Diagnostics (IVD) for early disease detection enables physicians to implement suitable treatments more efficiently. For instance, based on a factsheet by the WHO in September 2022, Non-Communicable Diseases (NCDs) accounted for 41 million deaths, representing approximately 74% of all global fatalities.

In the global in vitro diagnostics market, the increasing burden of diseases can be effectively addressed through enhanced awareness of early diagnosis and the optimal use of in-vitro diagnostics (IVD) at both patient and physician levels. The aging population's heightened vulnerability to various conditions, including hypertension, diabetes, cardiovascular, liver, and kidney diseases, has resulted in greater adoption of homecare IVD devices.

For example, as reported by the United Nations in January 2023, the global population of individuals aged 65 years and older was 761 million in 2021, and this number is projected to increase to 1.6 billion by 2050. The population of those aged 80 years or older is growing even faster.

Increasing Adoption of Point-of-Care Testing Devices

As the burden of diseases continues to increase, medical device companies are diligently working on developing technologically advanced diagnostic devices. In response, hospitals and laboratories are growing inclined towards point-of-care testing devices, seeking accurate real-time data. Point-of-care (PoC) testing is conducted near the patient, typically requiring only a small blood sample, and delivers rapid test results for immediate clinical decision-making. This capability enables doctors to make prompt treatment decisions without waiting for results from a central laboratory.

FUJIFILM Sonosite, Inc. revealed its plans to introduce the Sonosite PX ultrasound system in India in January 2023. This new product launch aims to enhance clinician ergonomics and efficiency for improved medical performance.

For instance, in August 2023, Anbio Biotechnology launched a handheld analyzer based on the LAMP (Loop-Mediated Isothermal Amplification) diagnostic technique for rapid point-of-care testing to enter the point-of-care testing market.

Increasing Funding and Government Support

In the global in vitro diagnostics market, government organizations, associations, and agencies are actively promoting the utilization of IVD through awareness initiatives, thereby fostering market growth. The World Health Organization (WHO) has introduced a model list of Essential In-Vitro Diagnostics for primary healthcare and medical facilities equipped with clinical laboratories to emphasize the importance of addressing diseases based on their burden and prevalence. These categories are further subdivided to cover general IVDs and specific diseases.

For instance, in November 2023, the National Institute for Health and Care Research under the United Kingdom government awarded a fund of GBP 3 million to Newcastle Health-tech Research Centre to support a five-year program and develop innovative technology solutions in in-vitro diagnostics for improved and efficient diagnosis of people across the country.

Dominance of Immunodiagnostics and Growth in Molecular Diagnostics

The immunodiagnostics segment is anticipated to be the leading segment during the assessment period in the market with 35.22% of value share in 2022 while the molecular diagnostics segment is expected to grow at a significantly higher pace with a CAGR of 7.1% during the forecast period. Rising cases of infectious diseases is resulting in a higher value share of the immunodiagnostics segment. The advances in the field of genetic and molecular research and its vast applications in diagnostics are driving the high growth rate for the molecular diagnostics segment.

For instance, in November 2023, based on the tried-and-true gold standard technology of the LightCycler Systems that came before it, Roche announced the launch of the LightCycler PRO System. This novel technology bridges the gap between in vitro diagnostics and translational research while raising the standard for performance and usability. Roche's molecular PCR testing offering, which features options for a range of healthcare professionals, is further enhanced with the LightCycler PRO System.

Reagents and Consumables is the Leading Segment

Based on product type, the in-vitro diagnostics market is segmented into reagents and consumables, instruments, and data management software. The reagents and consumables segment are anticipated to be the leading segment covering more than 65% of value share throughout the assessment period, owing to the regular consumption and frequent refiling of these in diagnostic laboratories. Instruments and software usually come in packages and are one-time purchases unlike reagents and consumables, thus contributing a lower share of revenue to the market. Growing demand for in-vitro diagnostic procedures is expected to propel the market share of these segments in the forecast years.

For instance, in June 2023, Kaneka Corporation received authorization for "KANEKA Immunochromatography Flu A/B & SARS-CoV-2 Ag" to manufacture and sell it. "KANEKA Immunochromatography Flu A/B & SARS-CoV-2 Ag" can detect COVID-19 (SARS-CoV-2) and influenza virus antigens in single sample collection. Earlier, the product was launched in May as an in-vitro diagnostic reagent. The suggested retail price of the product is 19,800 yen (for 10 tests) including taxes.

North America Dominates the In-vitro Diagnostics Market

North America is exerting its dominance in the In-vitro Diagnostics market. With high investment in research and development activities, technological advancements by key players, and highly advanced healthcare infrastructure in North American countries like the United States and Canada, the region is expected to dominate the market with the highest value share. The supportive government initiatives and favorable reimbursement scenario for managing the growing number of surgical procedures is also embracing the growth of the market in the region. Manufacturers are also gaining benefits from regulatory approvals and further market expansion. As per the American College of Rheumatology, approximately, 790,000 knee surgeries are performed annually in the United States.

For instance, in April 2023, the USFDA approved the MISHA Knee System, manufactured by Moximed, Inc. for marketing in the United States. MISHA Knee System is an implant placed alongside the knee joint which helps in reducing the weight load and saving knee damage without removing the knee joint.

Future Market Scenario (2023 - 2030F)

Growing prevalence of chronic diseases like cancer across the globe is driving the demand in the global in-vitro diagnostics market.

Growing technological advancement enhances the efficacy of diagnostic systems and is anticipated to propel market growth.

Immunodiagnostics is the leading segment in the in-vitro diagnostics market due to the high growth of infectious diseases while molecular diagnostics has the highest CAGR due to vast applications.

In-vitro diagnostics solutions will adapt to technological advancements to meet the needs of various customer segments.

Key Players Landscape and Outlook

Key participants in the In-vitro Diagnostics market include: F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., BD characterizes this landscape, as these companies compete to outperform one another in terms of patient compliance, safety, accuracy, and unique features. The market prognosis remains positive, owing to increased demand for in-vitro diagnostics procedures. In-vitro diagnostics manufacturers are actively involved in designing innovative solutions. Collaborations and developing technologies are projected to increase competition in this fast-paced market.

In January 2024, Roche announced a definitive agreement to acquire LumiraDx's point-of-care technology. Roche agreed to pay USD 295 million for the acquisition and up to USD 55 million for funding the venture until the deal gets completed in mid-2024. The acquisition offers a wide range of immunoassay and clinical chemistry tests to Roche, which have the potential for additional high-medical value in the future. The major focus area includes LumiraDx's CE-marked HbA1c test.

In March 2023, Abbott revealed that its Alinity I laboratory instrument, designed for diagnosing traumatic brain injuries (TBIs) and assessing concussions using two biomarkers, has obtained FDA approval, and is now set for commercial launch.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global In-vitro Diagnostics Market Outlook, 2016-2030F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product Type
    • 4.2.1. Instruments
    • 4.2.2. Reagents and Consumables
    • 4.2.3. Data Management Software
  • 4.3. By Techniques
    • 4.3.1. Immunodiagnostics
    • 4.3.2. Clinical Chemistry
    • 4.3.3. Molecular Diagnostics
    • 4.3.4. Microbiology
    • 4.3.5. Haematology
    • 4.3.6. Coagulation and Haemostasis
    • 4.3.7. Urinalysis
    • 4.3.8. Others
  • 4.4. By Settings
    • 4.4.1. Laboratories
    • 4.4.2. Point-of-Care
  • 4.5. By Application
    • 4.5.1. Ophthalmology
    • 4.5.2. Infectious Diseases
    • 4.5.3. Diabetes
    • 4.5.4. Drug Testing/ Pharmacogenomics
    • 4.5.5. Autoimmune Diseases
    • 4.5.6. Cardiology
    • 4.5.7. Oncology
    • 4.5.8. HIV/AIDS
    • 4.5.9. Nephrology
    • 4.5.10. Gastroenterology
    • 4.5.11. Others
  • 4.6. By End-user
    • 4.6.1. Clinical Laboratories
    • 4.6.2. Hospitals
    • 4.6.3. Point-of-care testing centres
    • 4.6.4. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. Asia-Pacific
    • 4.7.4. South America
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2022

5. Global In-vitro Diagnostics Market Outlook, By Region, 2016-2030F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product Type
      • 5.1.2.1. Instruments
      • 5.1.2.2. Reagents and Consumables
      • 5.1.2.3. Data Management Software
    • 5.1.3. By Techniques
      • 5.1.3.1. Immunodiagnostics
      • 5.1.3.2. Clinical Chemistry
      • 5.1.3.3. Molecular Diagnostics
      • 5.1.3.4. Microbiology
      • 5.1.3.5. Haematology
      • 5.1.3.6. Coagulation and Haemostasis
      • 5.1.3.7. Urinalysis
      • 5.1.3.8. Others
    • 5.1.4. By Settings
      • 5.1.4.1. Laboratories
      • 5.1.4.2. Point-of-Care
    • 5.1.5. By Application
      • 5.1.5.1. Ophthalmology
      • 5.1.5.2. Infectious Diseases
      • 5.1.5.3. Diabetes
      • 5.1.5.4. Drug Testing/ Pharmacogenomics
      • 5.1.5.5. Autoimmune Diseases
      • 5.1.5.6. Cardiology
      • 5.1.5.7. Oncology
      • 5.1.5.8. HIV/AIDS
      • 5.1.5.9. Nephrology
      • 5.1.5.10. Gastroenterology
      • 5.1.5.11. Others
    • 5.1.6. By End-user
      • 5.1.6.1. Clinical Laboratories
      • 5.1.6.2. Hospitals
      • 5.1.6.3. Point-of-care testing centres
      • 5.1.6.4. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. By Value
      • 5.1.7.2. By Product Type
      • 5.1.7.2.1. Instruments
      • 5.1.7.2.2. Reagents and Consumables
      • 5.1.7.2.3. Data Management Software
      • 5.1.7.3. By Techniques
      • 5.1.7.3.1. Immunodiagnostics
      • 5.1.7.3.2. Clinical Chemistry
      • 5.1.7.3.3. Molecular Diagnostics
      • 5.1.7.3.4. Microbiology
      • 5.1.7.3.5. Haematology
      • 5.1.7.3.6. Coagulation and Haemostasis
      • 5.1.7.3.7. Urinalysis
      • 5.1.7.3.8. Others
      • 5.1.7.4. By Settings
      • 5.1.7.4.1. Laboratories
      • 5.1.7.4.2. Point-of-Care
      • 5.1.7.5. By Application
      • 5.1.7.5.1. Ophthalmology
      • 5.1.7.5.2. Infectious Diseases
      • 5.1.7.5.3. Diabetes
      • 5.1.7.5.4. Drug Testing/ Pharmacogenomics
      • 5.1.7.5.5. Autoimmune Diseases
      • 5.1.7.5.6. Cardiology
      • 5.1.7.5.7. Oncology
      • 5.1.7.5.8. HIV/AIDS
      • 5.1.7.5.9. Nephrology
      • 5.1.7.5.10. Gastroenterology
      • 5.1.7.5.11. Others
      • 5.1.7.6. By End-user
      • 5.1.7.6.1. Clinical Laboratories
      • 5.1.7.6.2. Hospitals
      • 5.1.7.6.3. Point-of-care testing centres
      • 5.1.7.6.4. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2022

  • 6.1. By Product Type
  • 6.2. By Techniques
  • 6.3. By Settings
  • 6.4. By Application
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trial
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Case Studies

12. Key Players Outlook

  • 12.1. F. Hoffmann-La Roche AG
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products & Services
    • 12.1.4. Financials (As reported)
    • 12.1.5. Key Market Focus & Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Abbott Laboratories
  • 12.3. Danaher Corporation
  • 12.4. Siemens Healthineers AG
  • 12.5. Thermo Fisher Scientific Inc
  • 12.6. BD (Becton, Dickinson, and Company)
  • 12.7. Sysmex Corporation
  • 12.8. Illumina, Inc.
  • 12.9. Quidel Corp
  • 12.10. BioMerieux SA
  • 12.11. Charles River Laboratories
  • 12.12. Bio-Rad Laboratories, Inc
  • 12.13. DiaSorin S
  • 12.14. Agilent Technologies, Inc
  • 12.15. Qiagen
  • 12.16. Seegene Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

  • Table 1 Pricing Analysis of Products from Key Players
  • Table 2 Competition Matrix of Top 5 Market Leaders
  • Table 3 Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4 About Us - Region and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 3. Global In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 4. Global In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 5. Global In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 6. Global In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 7. Global In-vitro Diagnostics Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 10. North America In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 11. North America In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 12. North America In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 13. North America In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 14. North America In-vitro Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 17. United States In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 18. United States In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 19. United States In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 20. United States In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 21. Canada In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 23. Canada In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 24. Canada In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 25. Canada In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 26. Canada In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 27. Mexico In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 29. Mexico In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 30. Mexico In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 31. Mexico In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 32. Mexico In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 33. Europe In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 35. Europe In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 36. Europe In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 37. Europe In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 38. Europe In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 39. Europe In-vitro Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 42. Germany In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 43. Germany In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 44. Germany In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 45. Germany In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 46. France In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 48. France In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 49. France In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 50. France In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 51. France In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 52. Italy In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 54. Italy In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 55. Italy In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 56. Italy In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 57. Italy In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 60. United Kingdom In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 64. Russia In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 66. Russia In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 67. Russia In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 68. Russia In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 69. Russia In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 70. Netherlands In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 72. Netherlands In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 73. Netherlands In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 74. Netherlands In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 75. Netherlands In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 76. Spain In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 78. Spain In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 79. Spain In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 80. Spain In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 81. Spain In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 82. Turkey In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 84. Turkey In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 85. Turkey In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 86. Turkey In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 87. Turkey In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 88. Poland In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 90. Poland In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 91. Poland In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 92. Poland In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 93. Poland In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 94. South America In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 96. South America In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 97. South America In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 98. South America In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 99. South America In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 100. South America In-vitro Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 103. Brazil In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 104. Brazil In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 105. Brazil In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 106. Brazil In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 107. Argentina In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 109. Argentina In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 110. Argentina In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 111. Argentina In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 112. Argentina In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 115. Asia-Pacific In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific In-vitro Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 122. India In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 123. India In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 124. India In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 125. India In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 126. China In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 128. China In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 129. China In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 130. China In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 131. China In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 132. Japan In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 134. Japan In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 135. Japan In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 136. Japan In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 137. Japan In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 138. Australia In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 140. Australia In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 141. Australia In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 142. Australia In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 143. Australia In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 144. Vietnam In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 146. Vietnam In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 147. Vietnam In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 148. Vietnam In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 149. Vietnam In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 150. South Korea In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 152. South Korea In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 153. South Korea In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 154. South Korea In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 155. South Korea In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 156. Indonesia In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 158. Indonesia In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 159. Indonesia In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 160. Indonesia In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 161. Indonesia In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 162. Philippines In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 164. Philippines In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 165. Philippines In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 166. Philippines In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 167. Philippines In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 170. Middle East & Africa In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa In-vitro Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 177. Saudi Arabia In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 181. UAE In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 183. UAE In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 184. UAE In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 185. UAE In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 186. UAE In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 187. South Africa In-vitro Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa In-vitro Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 189. South Africa In-vitro Diagnostics Market Share, By Procedure Type, In USD Billion, 2016-2030F
  • Figure 190. South Africa In-vitro Diagnostics Market Share, By Implant Type, In USD Billion, 2016-2030F
  • Figure 191. South Africa In-vitro Diagnostics Market Share, By Device Type, In USD Billion, 2016-2030F
  • Figure 192. South Africa In-vitro Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Deployment Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Device Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By Industry Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022